Notes

Scheltens, P., Blennow, K., Breteler, M. M. B., de Strooper, B., Frisoni, G. B., Salloway, S., & van der Flier, W. M. (2016). Alzheimer’s disease. The Lancet, 388(10043), 505–517. https://doi.org/10.1016/s0140-6736(15)01124-1

Mesulam, M. M. (2013). Cholinergic circuitry of the human nucleus basalis and its fate in Alzheimer’s disease. Journal of Comparative Neurology, 521(18), 4124–4144. https://doi.org/10.1002/cne.23415

Nauta, W., Smith, G., Faull, R., & Domesick, V. B. (1978). Efferent connections and nigral afferents of the nucleus accumbens septi in the rat. Neuroscience, 3(4–5), 385–401. https://doi.org/10.1016/0306-4522(78)90041-6

Nardone, R., Höller, Y., Thomschewski, A., Kunz, A. B., Lochner, P., Golaszewski, S., Trinka, E., & Brigo, F. (2014). Dopamine differently modulates central cholinergic circuits in patients with Alzheimer disease and CADASIL. Journal of Neural Transmission, 121(10), 1313–1320. https://doi.org/10.1007/s00702-014-1195-1

Sarter, M., Lustig, C., Howe, W. M., Gritton, H., & Berry, A. S. (2014). Deterministic functions of cortical acetylcholine. European Journal of Neuroscience, 39(11), 1912–1920. https://doi.org/10.1111/ejn.12515

Hagena, H., & Manahan-Vaughan, D. (2016). Dopamine D1/D5, But not D2/D3, Receptor Dependency of Synaptic Plasticity at Hippocampal Mossy Fiber Synapses that Is Enabled by Patterned Afferent Stimulation, or Spatial Learning. Frontiers in Synaptic Neuroscience, 8. https://doi.org/10.3389/fnsyn.2016.00031

Nam, E., Derrick, J. S., Lee, S., Kang, J., Han, J., Lee, S. J. C., Chung, S. W., & Lim, M. H. (2018). Regulatory Activities of Dopamine and Its Derivatives toward Metal-Free and Metal-Induced Amyloid-β Aggregation, Oxidative Stress, and Inflammation in Alzheimer’s Disease. ACS Chemical Neuroscience, 9(11), 2655–2666. https://doi.org/10.1021/acschemneuro.8b00122

Kumar, U., & Patel, S. C. (2007). Immunohistochemical localization of dopamine receptor subtypes (D1R–D5R) in Alzheimer’s disease brain. Brain Research, 1131, 187–196. https://doi.org/10.1016/j.brainres.2006.10.049

Donthamsetti, P., Gallo, E. F., Buck, D. C., Stahl, E. L., Zhu, Y., Lane, J. R., Bohn, L. M., Neve, K. A., Kellendonk, C., & Javitch, J. A. (2018). Arrestin recruitment to dopamine D2 receptor mediates locomotion but not incentive motivation. Molecular Psychiatry, 25(9), 2086–2100. https://doi.org/10.1038/s41380-018-0212-4

Mitchell, R. A., Herrmann, N., & Lanctôt, K. L. (2010). The Role of Dopamine in Symptoms and Treatment of Apathy in Alzheimer’s Disease. CNS Neuroscience & Therapeutics, 17(5), 411–427. https://doi.org/10.1111/j.1755-5949.2010.00161.x

Rosenberg, P. B., Nowrangi, M. A., & Lyketsos, C. G. (2015). Neuropsychiatric symptoms in Alzheimer’s disease: What might be associated brain circuits? Molecular Aspects of Medicine, 43–44, 25–37. https://doi.org/10.1016/j.mam.2015.05.005

Martorana, A., & Koch, G. (2014). Is dopamine involved in Alzheimer’s disease? Frontiers in Aging Neuroscience, 6. https://doi.org/10.3389/fnagi.2014.00252

Jeon, J., Dencker, D., Wortwein, G., Woldbye, D. P. D., Cui, Y., Davis, A. A., Levey, A. I., Schutz, G., Sager, T. N., Mork, A., Li, C., Deng, C. X., Fink-Jensen, A., & Wess, J. (2010). A Subpopulation of Neuronal M4 Muscarinic Acetylcholine Receptors Plays a Critical Role in Modulating Dopamine-Dependent Behaviors. Journal of Neuroscience, 30(6), 2396–2405. https://doi.org/10.1523/jneurosci.3843-09.2010

Pan, X., Kaminga, A. C., Wen, S. W., Wu, X., Acheampong, K., & Liu, A. (2019). Dopamine and Dopamine Receptors in Alzheimer’s Disease: A Systematic Review and Network Meta-Analysis. Frontiers in Aging Neuroscience, 11. https://doi.org/10.3389/fnagi.2019.00175

Lester, D. B., Rogers, T. D., & Blaha, C. D. (2010). Acetylcholine-Dopamine Interactions in the Pathophysiology and Treatment of CNS Disorders. CNS Neuroscience & Therapeutics, 16(3), 137–162. https://doi.org/10.1111/j.1755-5949.2010.00142.x

H. Ferreira-Vieira, T., M. Guimaraes, I., R. Silva, F., & M. Ribeiro, F. (2016). Alzheimer’s disease: Targeting the Cholinergic System. Current Neuropharmacology, 14(1), 101–115. https://doi.org/10.2174/1570159x13666150716165726

Isola S, Hussain A, Dua A, et al. Metoclopramide. [Updated 2021 Sep 18]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2021 Jan-. Available from: https://www.ncbi.nlm.nih.gov/books/NBK519517/

Millan, M. J., Dekeyne, A., Gobert, A., Brocco, M., Mannoury la Cour, C., Ortuno, J. C., Watson, D., & Fone, K. (2020). Dual-acting agents for improving cognition and real-world function in Alzheimer's disease: Focus on 5-HT6 and D3 receptors as hubs. Neuropharmacology, 177, 108099. https://doi.org/10.1016/j.neuropharm.2020.108099

Lu J, Li X, Wang Q, Pei G. Dopamine D2 receptor and β-arrestin 2 mediate Amyloid-β elevation induced by anti-parkinson's disease drugs, levodopa and piribedil, in neuronal cells. PLoS One. 2017 Mar 2;12(3):e0173240. doi: 10.1371/journal.pone.0173240. PMID: 28253352; PMCID: PMC5333886.

Werner FM, Covenas R. Serotonergic Drugs: Agonists/Antagonists at Specific Serotonergic Subreceptors for the Treatment of Cognitive, Depressant and Psychotic Symptoms in Alzheimer's Disease. Curr Pharm Des. 2016;22(14):2064-71. doi: 10.2174/1381612822666160127113524. PMID: 26818863.

Mendonça Júnior, F. J., Scotti, L., Ishiki, H., Botelho, S. P., Da Silva, M. S., & Scotti, M. T. (2015). Benzo- and thienobenzo- diazepines: multi-target drugs for CNS disorders. Mini reviews in medicinal chemistry, 15(8), 630–647. https://doi.org/10.2174/1389557515666150219125030

McCormick, A. V., Wheeler, J. M., Guthrie, C. R., Liachko, N. F., & Kraemer, B. C. (2013). Dopamine D2 receptor antagonism suppresses tau aggregation and neurotoxicity. Biological psychiatry, 73(5), 464–471. https://doi.org/10.1016/j.biopsych.2012.08.027

Aronson MK, Ooi WL, Morgenstern H, Hafner A, Masur D, Crystal H, ... Katzman R. Women, myocardial infarction, and dementia in the very old. Neurology. 1990 Jul;40(7):1102-6. doi: 10.1212/wnl.40.7.1102.

Vladeanu, Matei PhD*; Giuffrida, Orazio PhD†; Bourne, Victoria J. DPhil‡ Prenatal Sex Hormone Exposure and Risk of Alzheimer Disease, Cognitive And Behavioral Neurology: June 2014 - Volume 27 - Issue 2 - p 102-106 doi: 10.1097/WNN.0000000000000024

Kondo, K., Suzuki, H., Handa, M., Nagahama, S., & Saruta, T. (1981). Effects of intracerebroventricular administration of dopamine and metoclopramide on blood pressure in rats. Archives internationales de pharmacodynamie et de therapie, 250(2), 273–278.

Castro, L., Varjão, B., Silva, I., Duque, B., Batista, A., Santana, R., Luz, P., Rocha, M. A., Jr, Fregoneze, J. B., & De Castro-e-Silva, E. (2001). Effect of the intracerebroventricular administration of GR 113808, a selective 5-HT4 antagonist, on water intake during hyperosmolarity and hypovolemia. Brazilian journal of medical and biological research = Revista brasileira de pesquisas medicas e biologicas, 34(6), 791–796. https://doi.org/10.1590/s0100-879x2001000600015